"Dinoprostone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa.
| Descriptor ID |
D015232
|
| MeSH Number(s) |
D10.251.355.255.550.250.200 D23.469.050.175.725.250.200
|
| Concept/Terms |
Dinoprostone- Dinoprostone
- PGE2 alpha
- alpha, PGE2
- Prostaglandin E2alpha
- E2alpha, Prostaglandin
- Prostaglandin E2
- E2, Prostaglandin
- Prostaglandin E2 alpha
- E2 alpha, Prostaglandin
- alpha, Prostaglandin E2
- PGE2
- PGE2alpha
|
Below are MeSH descriptors whose meaning is more general than "Dinoprostone".
Below are MeSH descriptors whose meaning is more specific than "Dinoprostone".
This graph shows the total number of publications written about "Dinoprostone" by people in this website by year, and whether "Dinoprostone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 3 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 1 | 3 | 4 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 3 | 4 |
| 2012 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dinoprostone" by people in Profiles.
-
Gulersen M, Zottola C, Li X, Krantz D, DiSturco M, Bornstein E. Chorioamnionitis after premature rupture of membranes in nulliparas undergoing labor induction: prostaglandin E2 vs. oxytocin. J Perinat Med. 2021 Nov 25; 49(9):1058-1063.
-
Gulersen M, DiSturco M, Krantz DA, Bornstein E. Comparison of two management options for labor induction following unsuccessful prostaglandin E2 ripening. J Matern Fetal Neonatal Med. 2022 May; 35(9):1759-1763.
-
Goncharova EA, Goncharov DA, Zhao H, Penn RB, Krymskaya VP, Panettieri RA. ß2-adrenergic receptor agonists modulate human airway smooth muscle cell migration via vasodilator-stimulated phosphoprotein. Am J Respir Cell Mol Biol. 2012 Jan; 46(1):48-54.
-
Xiang L, Hester RL, Fuller WL, Sebai ME, Mittwede PN, Jones EK, Aneja A, Russell GV. Orthopedic trauma-induced pulmonary injury in the obese Zucker rat. Microcirculation. 2010 Nov; 17(8):650-9.
-
Yan H, Deshpande DA, Misior AM, Miles MC, Saxena H, Riemer EC, Pascual RM, Panettieri RA, Penn RB. Anti-mitogenic effects of ß-agonists and PGE2 on airway smooth muscle are PKA dependent. FASEB J. 2011 Jan; 25(1):389-97.
-
Robertson FM, Simeone AM, Lucci A, McMurray JS, Ghosh S, Cristofanilli M. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer. 2010 Jun 1; 116(11 Suppl):2806-14.
-
Raval M, Frank PG, Laury-Kleintop L, Yan G, Lanza-Jacoby S. Celecoxib combined with atorvastatin prevents progression of atherosclerosis. J Surg Res. 2010 Oct; 163(2):e113-22.
-
Zheng Y, Ritzenthaler JD, Sun X, Roman J, Han S. Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1. Cancer Res. 2009 Feb 01; 69(3):896-904.
-
Ritzenthaler JD, Roman J, Han S. PPARbeta/delta agonist increases the expression of PGE2 receptor subtype EP4 in human lung carcinoma cells. Methods Mol Biol. 2009; 512:309-23.
-
Robertson FM, Simeone AM, Mazumdar A, Shah AH, McMurray JS, Ghosh S, Cristofanilli M. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol. 2008; 7(4):299-312.